BMO Capital: 'Strong Print Sets Amgen (AMGN) Shares Back on Track'

BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $335.00 price target on Amgen (NASDAQ: AMGN).

The analyst commented: "Commercial Execution Clears a Path to 2H25 Pipeline Catalysts; This quarter's strong print sets Amgen shares back on track into 2H data catalysts. Strength across all the company's business lines helped put together today's beat with notable out performance from less loved products like Otezla and the Horizon products (some inventory benefit in the quarter) helping to drive home today's beat. With 2Q earnings cleared in uncontroversial fashion focus now turns to the 2H catalyst path where we could be getting data for MariTide (Ph 2 obesity & T2D data), rocatinlimab (AD) and olpasiran (primary prevention)."

For an analyst ratings summary and ratings history on Amgen click here. For more ratings news on Amgen click here.

Shares of Amgen closed at $300.08 yesterday.

You May Also Be Interested In

• Amgen reports data breach involving patient and proprietary data
• Investing.com’s stocks of the week
• Pathfinder Bancorp (PBHC) Tops Q2 EPS by 42c